Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Syntara Limited ( (AU:SNT) ) just unveiled an update.
Syntara Limited has released an equity raising presentation outlining a placement of fully paid ordinary shares and a conditional second tranche placement to support its ongoing operations and strategic initiatives. The company underscores that its activities, including clinical trials and the sale of its mannitol business unit, are subject to significant known and unknown risks, and urges potential investors to independently assess these risks and seek professional advice given the potential impact on financial performance and shareholder value.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.19 price target. To see the full list of analyst forecasts on Syntara Limited stock, see the AU:SNT Stock Forecast page.
More about Syntara Limited
Syntara Limited is a healthcare company that develops pharmaceutical products and manages clinical trials, with a portfolio that has included a mannitol business unit. The company operates in a highly regulated, risk-sensitive sector where trial outcomes, product partnering and asset sales can materially affect its financial performance and strategic direction.
Average Trading Volume: 860,118
Technical Sentiment Signal: Sell
Current Market Cap: A$52.3M
Find detailed analytics on SNT stock on TipRanks’ Stock Analysis page.